# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medic...
– Approval triggers $10 million cash milestone payment to Verrica –– YCANTH® approval in Japan addresses significant unmet need...
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate ...